/*! This file is auto-generated */ .wp-block-button__link{color:#fff;background-color:#32373c;border-radius:9999px;box-shadow:none;text-decoration:none;padding:calc(.667em + 2px) calc(1.333em + 2px);font-size:1.125em}.wp-block-file__button{background:#32373c;color:#fff;text-decoration:none} Problem 12 What limits the use of differenc... [FREE SOLUTION] | 91影视

91影视

Log out

Learning Materials

Features

Discover

Chapter 22: Problem 12

What limits the use of differences in restriction enzyme sites as a way of detecting point mutations in human genes?

Short Answer

Expert verified
In summary, using differences in restriction enzyme sites to detect point mutations in human genes is limited due to several factors. These limitations include: most point mutations not occurring within the palindromic sequences recognized by restriction enzymes; the large genome size of humans; the restricted number of recognized sites by the thousands of known restriction enzymes; and the difficulty in detecting heterozygous mutations. Therefore, while restriction enzymes can be useful in detecting some specific mutations, their effectiveness in tracking point mutations in human genes is limited.

Step by step solution

01

Restriction Enzymes Basics

Restriction enzymes are proteins that recognize and cut specific DNA sequences. They are naturally produced by bacteria as a defense mechanism against foreign DNA. In molecular biology, they are widely used as tools for cloning, genetic engineering and DNA analysis.
02

Point Mutations

Point mutations are single nucleotide changes in a DNA sequence. There are three types of point mutations: Silent mutations, which do not change the amino acid; Missense mutations, which change the amino acid to another amino acid; and Nonsense mutations, which change the coding triplet to a stop codon.
03

Limitation 1: Palindromic Sequences

Restriction enzymes recognize specific palindromic sequences in the DNA, meaning that the sequence reads the same in the 5' to 3' direction on both strands. If a point mutation occurs within a site recognized by a specific restriction enzyme, it could disrupt the recognition site and prevent the enzyme from binding and cutting the DNA. However, many point mutations do not occur within these specific palindromic sequences and will not affect the restriction sites, making them difficult to detect using this method.
04

Limitation 2: Large Genome Size

Human genes are spread throughout a genome that is over 3 billion base pairs long. This size creates a challenge in locating and analyzing specific genes and their corresponding restriction enzyme sites. And since restriction enzymes recognize only specific sequences, detecting point mutations that do not alter a known restriction site may not be possible using this approach.
05

Limitation 3: Limited Number of Recognized Sites

Restriction enzymes recognize specific DNA sequences, and there are thousands of different restriction enzymes known, each recognizing a unique site. However, not every possible DNA sequence has a corresponding restriction enzyme that recognizes it. As a result, the inability of a restriction enzyme to recognize a specific mutation site can limit its use in detecting point mutations.
06

Limitation 4: Difficulty in Detecting Heterozygous Mutations

In cases where an individual has two different alleles of a gene (heterozygous), detecting a point mutation with restriction enzymes becomes more difficult. This is because the presence of the normal, non-mutated allele may mask the effects of the mutation, leading to a false negative result. Overall, while restriction enzymes have their utility in detecting specific mutations that alter recognized sites, there are limitations - such as the presence of point mutations outside of recognized sequences, the complex and large human genome, the limited number of recognized sites, and the challenge of detecting heterozygous mutations - that restrict their effectiveness in tracking point mutations in human genes.

Unlock Step-by-Step Solutions & Ace Your Exams!

  • Full Textbook Solutions

    Get detailed explanations and key concepts

  • Unlimited Al creation

    Al flashcards, explanations, exams and more...

  • Ads-free access

    To over 500 millions flashcards

  • Money-back guarantee

    We refund you if you fail your exam.

Over 30 million students worldwide already upgrade their learning with 91影视!

One App. One Place for Learning.

All the tools & learning materials you need for study success - in one app.

Get started for free

Most popular questions from this chapter

There are more than 1000 cloned farm animals in the United States. In the near future, milk from cloned cows and their offspring (born naturally) may be available in supermarkets. These cloned animals have not been transgenically modified, and they are no different than identical twins. Should milk from such animals and their natural-born offspring be labeled as coming from cloned cows or their descendants? Why?

Genes in their natural state cannot be patented. This policy allows research and use of natural products for the common good. What argument might be presented in favor of patenting genes or gene products?

Private companies are now offering personal DNA sequencing along with interpretation. What services do they offer? Do you think that these services should be regulated, and if so, in what way?

(a) Would you agree with Judge Sweet's ruling to invalidate the patenting of the \(B R C A 1\) and \(B R C A 2\) genes? If you were asked to judge the patenting of the direct-to-consumer test for the \(B R C A 1\) and \(B R C A 2\) genes, how would you rule? (b) \(\mathrm{J}\). Craig Venter has filed a patent application for his "firstever human made life form." This patent is designed to cover the genome of \(M .\) genitalium. Would your ruling for Venter's "organism" be different from Judge Sweet's ruling on patenting of the \(B R C A 1\) and \(B R C A 2\) genes?

Dominant mutations can be categorized according to whether they increase or decrease the overall activity of a gene or gene product. Although a loss-of- function mutation (a mutation that inactivates the gene product) is usually recessive, for some genes, one dose of the normal gene product, encoded by the normal allele, is not sufficient to produce a normal phenotype. In this case, a loss-of-function mutation in the gene will be dominant, and the gene is said to be haploinsufficient. A second category of dominant mutation is the gain- of-function mutation, which results in a new activity or increased activity or expression of a gene or gene product. The gene therapy technique currently used in clinical trials involves the "addition" to somatic cells of a normal copy of a gene. In other words, a normal copy of the gene is inserted into the genome of the mutant somatic cell, but the mutated copy of the gene is not removed or replaced. Will this strategy work for either of the two aforementioned types of dominant mutations?
See all solutions

Recommended explanations on Biology Textbooks

Biological Molecules

Read Explanation

Control of Gene Expression

Read Explanation

Bioenergetics

Read Explanation

Cell Cycle

Read Explanation

Genetic Information

Read Explanation

Biology Experiments

Read Explanation
View all explanations

What do you think about this solution?

We value your feedback to improve our textbook solutions.

Study anywhere. Anytime. Across all devices.